News
Biogen Idec Explains Company's Move Away from Venture Funding
www.genengnews.com
[Genetic Engineering News] - Earlier this week Bruce Booth of Atlas Venture impressively documented on his blog Life Sci VC the growth of corporate VC over the past decade, but every rule has an exception, judging from Xconomy's interview with Steven H. Holtzman of Biogen Idec.
Growth of Corporate Ventures Reflected in Rising VC Numbers
www.genengnews.com
[Genetic Engineering News] - Writing in his blog Life Sci VC, Bruce Booth, a partner at Atlas Venture, offered one likely explanation that didn't surface in most of the news accounts of VC activity: the rise of corporate venture funds. “Corporate venture capital's role in the new
VCs pump more cash into late-stage efforts as startup rounds shrivel
www.fiercebiotech.com
[FierceBiotech] shunning companies that are years away from any prospective exit in an IPO-poor environment, Big Pharma groups have been stepping up to the plate via their corporate venture capital (CVC) units, as Atlas' Bruce Booth notes in his column today.
Big drugmakers lend hand in forming biotech startups
www.fiercebiotech.com
[FierceBiotech] - Bruce Booth, a partner focused on early-stage biotech investing at Atlas Venture, writes about the trend on his blog this morning. Big Pharma's growing role in launching new startups made big news this week, as Sanofi ($SNY) led the charge with its
sorted by relevance / date